AAAAAA

   
Results: 1-10 |
Results: 10
Sequential docetaxel and vinorelbine for patients with advanced breast cancer previously treated with anthracyclines: A phase II study
Authors: Brugnatelli, S Riccardi, A Danova, M Pugliese, P Tinelli, C Luchena, G Bernardo, A Giardina, G Fava, S Montanari, G Pedrotti, C Poli, AM
Citation: S. Brugnatelli et al., Sequential docetaxel and vinorelbine for patients with advanced breast cancer previously treated with anthracyclines: A phase II study, ONCOL REP, 8(4), 2001, pp. 801-805
Adult height and proteinuria in type 2 diabetes
Authors: Fava, S Azzopardi, J Watkins, PJ Hattersley, AT
Citation: S. Fava et al., Adult height and proteinuria in type 2 diabetes, NEPH DIAL T, 16(3), 2001, pp. 525-528
DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma
Authors: Lazzarino, M Corso, A Barbarano, L Alessandrino, E Cairoli, R Pinotti, G Ucci, G Uziel, L Rodeghiero, F Fava, S Ferrari, D Fiumano, M Frigerio, G Isa, L Luraschi, A Montanara, S Morandi, S Perego, D Santagostino, A Savare, M Vismara, A Morra, E
Citation: M. Lazzarino et al., DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma, BONE MAR TR, 28(9), 2001, pp. 835-839
ACE gene polymorphism as a prognostic indicator in patients with type 2 diabetes and established renal disease
Authors: Fava, S Ellard, S Azzopardi, J Hattersley, AT
Citation: S. Fava et al., ACE gene polymorphism as a prognostic indicator in patients with type 2 diabetes and established renal disease, DIABET CARE, 24(12), 2001, pp. 2115-2120
A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PVBC 97/01)
Authors: Riccardi, A Pugliese, P Danova, M Brugnatelli, S Grasso, D Giordano, M Bernardo, G Giardina, G Fava, S Montanari, G Pedrotti, C Trotti, G Rinaldi, E Poli, M Tinelli, C
Citation: A. Riccardi et al., A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PVBC 97/01), BR J CANC, 85(2), 2001, pp. 141-146
Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: a prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer
Authors: Riccardi, A Tinelli, C Brugnatelli, S Pugliese, P Giardina, V Giordano, M Danova, M Richetti, A Fava, S Rinaldi, E Fregoni, V Trotti, G Poli, A
Citation: A. Riccardi et al., Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: a prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer, INT J ONCOL, 16(4), 2000, pp. 769-776
Prevention of cisplatin-induced delayed emesis: still unsatisfactory
Authors: Ruggeri, B Ballatori, E Roila, F De Angelis, V Tonato, M Del Favero, A Ciccarese, G Basurto, C Ciccarese, G Palladino, MA Porrozzi, S Picciafuoco, M Contu, SA Olmeo, N Pazzola, A Pilo, L Tateo, PS Salamano, S Morana, S Lucchino, S Ricci, S Antonuzzo, A Allegrini, G Galli, L Conte, PF Massidda, B Ionta, MT Scanu, A Murru, R Picece, V Nicodemo, M Recaldin, E Nuzzo, A Laudadio, L D'Ostilio, N Locatelli, MC D'Antona, A Luporini, G Scagliotti, G Selvaggi, G Mattei, A Favalli, G Gambino, A Fava, S Grimi, E Fava, S Grimi, E Scarfone, G Bolis, MC Alessandroni, P Catalano, G Boni, C Moretti, G Cortesi, E Martelli, O Antimi, M Bellini, V Buzzi, F Brugia, M Grecchi, G Clerico, M Montinari, F Donati, D Sansoni, E
Citation: B. Ruggeri et al., Prevention of cisplatin-induced delayed emesis: still unsatisfactory, SUPP CARE C, 8(3), 2000, pp. 229-232
Increased prevalence of proteinuria in diabetic sibs of proteinuric type 2diabetic subjects
Authors: Fava, S Azzopardi, J Hattersley, AT Watkins, PJ
Citation: S. Fava et al., Increased prevalence of proteinuria in diabetic sibs of proteinuric type 2diabetic subjects, AM J KIDNEY, 35(4), 2000, pp. 708-712
Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy
Authors: Roila, F Ballatori, E Ruggeri, B De Angelis, V Tonato, M Bosnjak, S Del Favero, A Ciccarese, G Basurto, C Ciccarese, G Palladino, MA Porozzi, S Marinkovic, Z Neskovic-Konstantinovic, Z Susnjar, S Vasovic, S Colakovic, S Lukic, V Radosavljevic, D Fava, S Grimi, E Calcagno, A De Paoli, A Luoni, M Tocci, A Nuzzo, A Laudadio, L Di Blasio, A Sacco, M Contu, A Olmeo, N Pazzola, A Baldino, G Picece, V Nicodemo, M Cirillo, M Recaldin, E Dazzi, C Cariello, A Giovanis, P Zumaglini, F Rosati, G Manzione, L Bilancia, D Rossi, A Donati, D Maccaferri, R Malacarne, P Labianca, R Quadri, A Pessi, MA Cortesi, E Martelli, O Giuliodori, L Silva, RR Mari, D Massidda, B Ionta, MT Alessandroni, P Baldelli, A Antimi, M Minelli, M Gridelli, C Rossi, A Passalacqua, R Quarta, M Sassi, M Pinaglia, D De Marino, E Giampaolo, MA Ciancola, F Lalli, A Di Felice, S Casartelli, C
Citation: F. Roila et al., Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy, N ENG J MED, 342(21), 2000, pp. 1554-1559
Myeloprotective effect of early primary granulocyte-colony stimulating factor during six courses of intensified 5-fluorouracil, epirubicin and cyclophosphamide (120FEC) chemotherapy for advanced breast cancer
Authors: Riccardi, A Brugnatelli, S Giordano, M Danova, M Pugliese, P Tinelli, C Klersy, C Richetti, A Fava, S Nastasi, G Rinaldi, E Fregoni, V De Monte, A Trotti, G Bovio, A Ascari, E
Citation: A. Riccardi et al., Myeloprotective effect of early primary granulocyte-colony stimulating factor during six courses of intensified 5-fluorouracil, epirubicin and cyclophosphamide (120FEC) chemotherapy for advanced breast cancer, TUMORI, 84(5), 1998, pp. 540-546
Risultati: 1-10 |